BIOMAT Database Logo BIOMAT Database Logo

Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect. 2021

Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.

A new series of quinoline derivatives of combretastatin A-4 have been designed, synthesised and demonstrated as tubulin polymerisation inhibitors. These novel compounds showed significant antiproliferative activities, among them, 12c exhibited the most potent inhibitory activity against different cancer cell lines (MCF-7, HL-60, HCT-116 and HeLa) with IC50 ranging from 0.010 to 0.042 µM, and with selectivity profile against MCF-10A non-cancer cells. Further mechanistic studies suggest that 12c can inhibit tubulin polymerisation and cell migration, leading to G2/M phase arrest. Besides, 12c induces apoptosis via a mitochondrial-dependant apoptosis pathway and caused reactive oxygen stress generation in MCF-7 cells. These results provide guidance for further rational development of potent tubulin polymerisation inhibitors for the treatment of cancer.HighlightsA novel series of quinoline derivatives of combretastatin A-4 have been designed and synthesised.Compound 12c showed significant antiproliferative activities against different cancer cell lines.Compound 12c effectively inhibited tubulin polymerisation and competed with [3H] colchicine in binding to tubulin.Compound 12c arrested the cell cycle at G2/M phase, effectively inducing apoptosis and inhibition of cell migration.

UI MeSH Term Description Entries
D011804 Quinolines
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013267 Stilbenes Organic compounds that contain 1,2-diphenylethylene as a functional group. Stilbene,Stilbene Derivative,Stilbene Derivatives,Stilbenoid,Stilbenoids,Derivative, Stilbene,Derivatives, Stilbene
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin

Related Publications

Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Design, concise synthesis and evaluation of novel amide-based combretastatin A-4 analogues as potent tubulin inhibitors.
May 2024, Bioorganic & medicinal chemistry letters,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities.
April 2021, Journal of medicinal chemistry,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Novel cyanocombretastatins as potent tubulin polymerisation inhibitors.
November 2012, Bioorganic & medicinal chemistry letters,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors.
March 2013, Organic and medicinal chemistry letters,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Discovery of novel arylamide derivatives containing piperazine moiety as inhibitors of tubulin polymerisation with potent liver cancer inhibitory activity.
December 2023, Journal of enzyme inhibition and medicinal chemistry,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Molecular modeling study, synthesis and biological evaluation of combretastatin A-4 analogues as anticancer agents and tubulin inhibitors.
February 2018, MedChemComm,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Synthesis and antitumor activity of litseaone B analogues as tubulin polymerisation inhibitors.
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Design, synthesis and biological evaluation of novel vicinal diaryl-substituted 1H-Pyrazole analogues of combretastatin A-4 as highly potent tubulin polymerization inhibitors.
November 2019, European journal of medicinal chemistry,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity.
December 2017, Bioorganic chemistry,
Tarek S Ibrahim, and Mohamed M Hawwas, and Azizah M Malebari, and Ehab S Taher, and Abdelsattar M Omar, and Thikryat Neamatallah, and Zakaria K Abdel-Samii, and Martin K Safo, and Yaseen A M M Elshaier
A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors.
October 2020, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!